FDA Final Guidance: Patient Preference Information Over Product Life Cycle

Published in response to: Federal Register, March 30, 2026 — Docket No. FDA-2026-06063

On March 30, 2026, the U.S. Food and Drug Administration (FDA) published its final guidance entitled "Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle." For medical device manufacturers, sponsors, and quality management professionals, this guidance is not a bureaucratic footnote — it is a strategic inflection point. If your organization has been treating patient input as a soft, nice-to-have element of your development process, this guidance signals that the FDA now expects a structured, documented, and lifecycle-integrated approach to Patient Preference Information (PPI).

In this article, I'll break down what the guidance actually says, where it fits within your existing ISO 13485:2016 quality management framework, and — most importantly — what you need to do differently starting now.

What Is Patient Preference Information (PPI)?

Patient Preference Information (PPI) refers to qualitative or quantitative information about the relative desirability or acceptability to patients of attributes that differ among alternative health interventions. In plain terms, it captures what patients actually care about: how a device feels to use, which side effects they find tolerable, how important ease-of-use is relative to clinical efficacy, and what tradeoffs they are willing to accept.

PPI is distinct from clinical outcome data. It does not tell you whether a device works — it tells you whether patients want it to work that way. That distinction matters enormously during benefit-risk assessments, premarket submissions, and post-market surveillance activities.

The FDA has been building toward this framework for years. The 21st Century Cures Act (enacted December 2016) explicitly directed the FDA to develop methods for collecting and using patient preference data. This final guidance represents the culmination of that legislative mandate, incorporating years of pilot programs, draft guidance feedback, and real-world PPI submissions.

Key Principles of the Final Guidance

The FDA's final guidance articulates several foundational principles that sponsors should internalize. Here is a structured overview:

1. PPI Is Voluntary — But Strategically Important

The guidance is explicit: submitting PPI is not mandatory. However, FDA makes equally clear that when PPI is submitted — and when it is methodologically sound — it will be considered in regulatory decision-making. That creates a powerful asymmetry: sponsors who invest in robust PPI collection gain a demonstrable voice in benefit-risk discussions, while those who don't may find themselves at a disadvantage when their benefit-risk profile is marginal or contested.

Citation hook: The FDA's final guidance on patient preference information establishes that while PPI submission remains voluntary, well-collected PPI may directly influence benefit-risk determinations in premarket review and post-market regulatory decisions.

2. PPI Should Span the Total Product Life Cycle (TPLC)

This is the most operationally significant element of the guidance. PPI is not just a premarket activity. The FDA explicitly recommends that sponsors consider PPI at every phase:

This lifecycle framing maps directly onto the ISO 13485:2016 product realization and post-market feedback requirements. If you have a strong QMS in place, you already have the procedural architecture to integrate PPI — it's largely a matter of activating it.

3. Methodological Rigor Is Non-Negotiable

The FDA does not prescribe a single method for collecting PPI, but it does set clear expectations for scientific rigor. Acceptable methods discussed in the guidance include:

• Discrete Choice Experiments (DCE) — patients choose between hypothetical device scenarios with different attribute combinations
• Best-Worst Scaling (BWS) — patients rank most and least important attributes
• Threshold Technique — patients indicate minimum acceptable benefit thresholds for given risks
• Qualitative methods — interviews, focus groups, concept elicitation

Regardless of method, FDA expects sponsors to document: the study design rationale, patient population representativeness, how attributes and levels were identified (including patient input in that process), and how results were interpreted and translated into regulatory conclusions.

This is a quality systems challenge as much as a clinical one. The documentation and validation requirements for PPI studies are analogous to design validation under ISO 13485 §7.3.7 — you need to show that your methods produced meaningful, reliable data that represents the intended patient population.

4. FDA Will Incorporate PPI Into Its Own Decision-Making

Perhaps the most significant signal in this guidance is the FDA's commitment to transparency about how it uses PPI. The agency describes its own internal processes for weighing PPI evidence during benefit-risk assessments, and it acknowledges that PPI — when robust — can shift a regulatory determination.

Citation hook: According to the FDA's March 2026 final guidance, the agency will incorporate submitted PPI into benefit-risk framework analyses, meaning that a sponsor's investment in patient preference research can directly affect premarket approval outcomes and post-market label negotiations.

Why This Guidance Matters Right Now: Industry Context

This guidance arrives at a moment when the FDA's benefit-risk framework is under increasing scrutiny — from patient advocacy groups who want more patient voice in approvals, and from industry groups who want predictable, evidence-based standards. Several data points frame the significance of this moment:

• According to the FDA's own benefit-risk framework documentation, the agency has cited patient preference evidence in over 30 premarket device decisions since initiating its PPI pilot programs in 2015 — a number expected to rise substantially under this formalized guidance.
• A 2023 study published in Value in Health found that fewer than 15% of medical device submissions to FDA included quantitative patient preference data, despite a decade of FDA encouragement — indicating significant competitive white space for sponsors who lead on PPI.
• The Medical Device Innovation Consortium (MDIC) has estimated that incorporating patient-centered endpoints into device development can reduce late-stage clinical trial failures by up to 20% by aligning device performance attributes with what patients actually value.
• The FDA's Center for Devices and Radiological Health (CDRH) strategic priorities for 2024–2027 explicitly list patient-centered device development as a top-tier initiative, of which this guidance is a direct output.
• Under ISO 13485:2016, clause 8.2.1 requires organizations to establish documented procedures for gathering post-market feedback, and clause 7.3.3 requires patient needs to be translated into design inputs — creating a natural regulatory and quality system alignment point for PPI integration.

Citation hook: Industry data suggests that fewer than 15% of medical device premarket submissions currently include quantitative patient preference information, creating a meaningful competitive and regulatory advantage for early adopters of structured PPI programs.

Implications for Your ISO 13485 Quality Management System

I've spent 8+ years helping over 200 medical device companies build and defend their quality management systems, and I can tell you that the organizational failure point with new FDA guidances is almost always the same: companies read the guidance, acknowledge it's important, and then do nothing procedural about it. By the time an audit or submission review surfaces the gap, months or years have passed.

Here is where I recommend you focus your QMS integration work:

Design Controls (ISO 13485 §7.3)

The most immediate integration point is design inputs (§7.3.3). PPI should directly inform the development of design inputs — the documented requirements that your device is designed to meet. When patient preference data tells you that patients prioritize ease of self-administration over reducing injection site reactions by 15%, that is a design input with traceable evidentiary basis. Document the PPI study, document the translation logic, and include it in your Design History File (DHF).

Design validation (§7.3.7) is also affected. If you claim your device meets patient needs, you now have a mechanism — and arguably an expectation — to demonstrate that PPI evidence supports that claim.

Risk Management (ISO 14971)

Patient preferences are directly relevant to the benefit-risk estimation required under ISO 14971. When estimating whether a risk is acceptable given anticipated benefits, PPI data provides an empirical basis for understanding how the intended patient population weighs those tradeoffs — which is far more defensible than internal engineering assumptions alone.

Post-Market Surveillance (ISO 13485 §8.2)

The FDA's guidance explicitly asks sponsors to consider whether post-market patient experience aligns with pre-market PPI findings. This creates a feedback loop that your PMS/PMSR process should capture. Consider adding a PPI-alignment review as part of your periodic safety update report (PSUR) or post-market surveillance report (PMSR) process.

Document Control and SOPs (ISO 13485 §4.2)

You will need documented procedures governing: - How and when PPI studies are initiated - Who is responsible for PPI methodology review and approval - How PPI data is stored, controlled, and referenced in submissions - How PPI findings are communicated to design, clinical, and regulatory affairs teams

If your organization does not have an SOP for patient preference information collection, that gap needs to close — not eventually, but on your next SOP review cycle.

What Makes a PPI Submission "Good" in FDA's Eyes?

Based on the guidance text and my experience reviewing regulatory submissions, here are the differentiating factors between PPI evidence that moves the needle and PPI evidence that gets footnoted and ignored:

Strategic Recommendations for Device Manufacturers

Based on my analysis of the guidance and the regulatory environment, here are my practical recommendations:

1. Conduct a PPI gap assessment now. Map your current product portfolio and pipeline against the TPLC stages in the guidance. Where are you collecting patient input? Where are you not? The gaps are your action items.

2. Integrate PPI into your next design project from Day 1. Don't retrofit PPI into a development program that is already in clinical trials. The value of PPI is highest — and the cost is lowest — when it is built into concept development and design inputs from the start.

3. Build cross-functional PPI capability. PPI sits at the intersection of regulatory affairs, clinical affairs, marketing, and quality. No single function owns it. Assign a PPI lead and create a cross-functional working group responsible for methodology, execution, and submission integration.

4. Don't confuse patient engagement with PPI. Advisory board meetings, social media listening, and patient testimonials are valuable — but they are not PPI in the FDA's sense. The guidance sets a methodological bar. Know the difference and resource accordingly.

5. Prepare for FDA to ask questions about PPI in review. As this guidance becomes operationally embedded at CDRH, expect FDA reviewers to ask whether and how you collected PPI, particularly for devices with significant benefit-risk complexity (high-risk indications, novel mechanisms, devices used by vulnerable populations). Having a documented PPI strategy — even if your studies are modest — demonstrates regulatory maturity.

For organizations just beginning this journey, I'd recommend reviewing our overview of ISO 13485 design control requirements as a foundational starting point, and considering how post-market surveillance best practices can be extended to capture ongoing PPI signals.

The Bottom Line

The FDA's final guidance on incorporating voluntary patient preference information over the total product life cycle is a maturation signal. The agency is telling the industry: we take patient voice seriously, we have built infrastructure to use it, and we expect you to meet us there.

This is not a compliance burden — it is a competitive and strategic opportunity. Sponsors who develop rigorous, lifecycle-integrated PPI programs will have stronger submissions, more defensible benefit-risk cases, and better-designed products. Those who treat this as optional will eventually face a submission review — or a post-market crisis — where the absence of patient preference evidence becomes a material liability.

At Certify Consulting, we have helped 200+ medical device clients navigate exactly these kinds of regulatory evolution moments. If you want to assess your organization's readiness to implement a PPI program that aligns with this guidance and your ISO 13485 QMS, visit certify.consulting to start the conversation.

Frequently Asked Questions

Is patient preference information required for FDA submissions?

No. The FDA's March 2026 final guidance explicitly states that PPI submission is voluntary. However, when PPI is submitted and methodologically sound, FDA will incorporate it into benefit-risk analyses — making it a strategic advantage rather than a mere compliance checkbox.

How does patient preference information relate to ISO 13485?

PPI integrates directly with multiple ISO 13485:2016 clauses, particularly §7.3.3 (design inputs), §7.3.7 (design validation), and §8.2.1 (post-market feedback). Patient preferences should inform design inputs, support validation claims, and feed into ongoing post-market surveillance activities.

What methods does the FDA accept for collecting PPI?

The FDA does not mandate a single method. Accepted approaches include Discrete Choice Experiments (DCE), Best-Worst Scaling (BWS), the Threshold Technique, and qualitative methods such as interviews and focus groups. The key requirement is scientific rigor: documented methodology, representative patient samples, and transparent interpretation of results.

When in the product life cycle should PPI be collected?

The guidance recommends PPI consideration at every stage of the Total Product Life Cycle — from early concept development through clinical trials, post-approval, and post-market surveillance. The most impactful PPI is collected early, during concept development and design inputs, where it can genuinely shape device attributes and tradeoffs.

What is the difference between patient engagement and patient preference information?

Patient engagement activities — such as advisory boards, patient testimonials, or social media listening — are valuable but do not constitute PPI in the FDA's framework. PPI requires structured, validated methods that quantify how patients weight specific device attributes and tradeoffs. The methodological bar is meaningfully higher than general patient engagement.

Last updated: 2026-04-10

Jared Clark, JD, MBA, PMP, CMQ-OE, CQA, CPGP, RAC is the Principal Consultant at Certify Consulting, with 8+ years of experience and a 100% first-time audit pass rate across 200+ medical device clients. Learn more at certify.consulting.